Accessibility Menu
Lexeo Therapeutics logo

Lexeo Therapeutics(NASDAQ) LXEO

Market Cap$357.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-55%
5 YearN/A
1 Year-4%
1 Month-5%
$4.54
+2.02%
+0.09Today
After hours$4.54+$0.00 (+0.00%)
Lexeo Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.552026-08-06
Lexeo Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.6%USD 4.352026-07-30
1 month-5.01%USD 4.792026-07-07
3 month-21.96%USD 5.832026-05-08
Year to date-54.18%USD 9.932025-12-31
1 year-4.41%USD 4.762025-08-06
Since inception-54.73%USD 10.052023-11-03

Lexeo Therapeutics Financials at a Glance

Market Cap

$357.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$87.50M

EPS (TTM)

-$1.45

P/E Ratio

-3.13

Dividend

$0.00

Beta (Volatility)

1.95 (High)

Price

$4.54

Volume

7

Open

$4.57

Previous Close

$4.55

Daily Range

$4.40 - $4.71

52-Week Range

$3.99 - $10.99

Estimated Earnings Date

Aug 13, 2026

LXEO News

Foolcom-Featured.png

Lexeo Reports Q2 Loss as Costs Jump 129%

Motley Fool Markets TeamAug 14, 2025

LXEO: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lexeo Therapeutics

Lexeo Therapeutics treats heart and brain diseases using genetic science. These medicines help patients with rare, life-threatening genetic conditions. The company fixes underlying causes rather than just treating symptoms.

Targeting the Genes

  • LX2006: Medicine for heart disease caused by Friedreich ataxia, a rare genetic disorder; currently in clinical trials.
  • LX2020: Treatment for heart muscle disease linked to specific mutations in the PKP2 gene.
  • LX2021: Therapy candidate for inherited heart conditions involving a high risk of sudden death.
  • LX2022: Genetic treatment for a common form of inherited heart muscle thickening.
  • Alzheimer's Portfolio: Group of therapies targeting genetic drivers of memory loss; currently seeking development partners.

Building the Business

  • Licensed clinical data and patents from Cornell University in April 2024 to support heart programs.
  • Maintained a technology partnership with Adverum, which was acquired by Eli Lilly and Company in late 2025.
  • Acquired Stelios Therapeutics, Inc. in August 2021 to expand the heart disease pipeline.
  • Updated a license with The Regents of the University of California in November 2025 for heart thickening research.
  • Announced plans in January 2025 to find strategic partners for Alzheimer's disease development.

A Smarter Way to Build

The company uses a specialized Sf9-baculovirus process to manufacture its viral vectors. This system allows for high-density production that is more efficient than standard industry methods.

The Latest Financial Data

  • Operating income was -$23.1 million in Q4 2025, improving 15.6% from Q4 2024.
  • Net income hit -$20.9 million in Q4 2025, an improvement of 19.3% year-over-year.
  • Free cash flow reached -$20.1 million in Q4 2025, improving 29.1% from Q4 2024.
  • Market capitalization grew to $758.2 million in Q4 2025, up 248.4% from Q4 2024.

Evolution of a Medicine Maker

Lexeo Therapeutics has transitioned from early research to clinical testing of genetic heart treatments. Its specialized manufacturing and targeted licensing support its focus on rare cardiovascular diseases.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

59

CEO

R. Nolan Townsend, MBA

Website

www.lexeotx.com

Headquarters

New York City, NY 10010, US

LXEO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-47.48%

Return on Capital

-42.92%

Return on Assets

-34.95%

Earnings Yield

-31.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$357.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.52M

Volume

7

Avg. Volume

920.83K

Financials (TTM)

Gross Profit

-$546.00K

Operating Income

-$97.79M

EBITDA

-$85.19M

Operating Cash Flow

-$97.99M

Capital Expenditure

-$432.00K

Free Cash Flow

-$98.42M

Cash & ST Invst.

$71.77M

Total Debt

$7.37M

Lexeo Therapeutics Performance Analysis

Lexeo Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 654,000-60.5%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lexeo Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Lexeo Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.2217.1%
20232023-12-31USD -2.4912.0%
20242024-12-31USD -3.0924.1%
20252025-12-31USD -1.86-39.8%
Lexeo Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3039.4%
Q32025-09-3045.0%
Q42025-12-3118.2%
Q12026-03-317.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$546.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$357.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.06M

N/A

Employees

59

N/A

Net Income

-$20.20M

+38.2%

EBITDA

-$19.63M

+38.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$71.77M

-28.1%

Total Debt

$7.37M

-21.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.67M

-30.8%

Short Term Debt

$2.70M

+1.8%

Return on Assets

-34.95%

N/A

Return on Invested Capital

-41.41%

N/A

Free Cash Flow

-$21.18M

+2.5%

Operating Cash Flow

-$21.14M

+2.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DBVTDBV Technologies S.A.
$13.74-3.51%
VNDAVanda Pharmaceuticals Inc.
$5.12+0.49%
AMRNAmarin Corporation plc
$14.26-1.04%
LRMRLarimar Therapeutics, Inc.
$4.20+2.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
SPCXSpace Exploration Technologies
$114.92+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%

Questions About LXEO

What is the current price of Lexeo Therapeutics?

Lexeo Therapeutics is trading at $4.55 per share.

What is the 52-week range for Lexeo Therapeutics?

Over the past 52 weeks, Lexeo Therapeutics has traded between $3.99 and $10.99.

How much debt does Lexeo Therapeutics have?

As of the most recent reporting period, Lexeo Therapeutics reported total debt of $7.37M.

How much cash does Lexeo Therapeutics have on hand?

Lexeo Therapeutics reported $71.77M in cash and cash equivalents in its most recent financial results.

What is Lexeo Therapeutics’s dividend yield?

Lexeo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services